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Abstract More than 50 % of patients with colorectal cancer
develop liver metastases. Surgical resection is the only avail-
able treatment that improves survival in patients with colorec-
tal liver metastases (CRLM). New antiangiogenic targeted
therapies, such as bevacizumab, aflibercept, and regorafenib,
in combination with neoadjuvant and conversion chemother-
apy may lead to improved response rates in this population of
patients and increase the proportion of patients eligible for
surgical resection. The present review discusses the available
data for antiangiogenic targeted agents in this setting. One of
these therapies, bevacizumab, which targets the vascular en-
dothelial growth factor (VEGF) has demonstrated good results
in this setting. In patients with initially unresectable CRLM,
the combination of 5-fluorouracil, leucovorin, and oxaliplatin
(FOLFOX) plus bevacizumab has led to high response and
resection rates. This combination is also effective for patients
with unresectable CRLM. Moreover, the addition of
bevacizumab to chemotherapy in the neoadjuvant setting of
liver metastasis has a higher impact on pathological response
rate. This drug also has a manageable safety profile, and ac-
cording to recent data, bevacizumab may protect against the
sinusoidal dilation provoked in the liver by certain cytotoxic
agents. In phase II trials, antiangiogenic therapy has demon-
strated benefits in the presurgical treatment of CRLM andmay
represent a new treatment pathway for these patients.
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Introduction
Colorectal cancer is the second most common cause of death
due to cancer in the western world. Worldwide, this disease is
the third most common cause of death in women and the
fourth in men [1]. There are several risk factors associated
with the development of colorectal cancer such as obesity,
low consumption of fruit and vegetables, a sedentary lifestyle
and smoking [2–4]. These factors result in significant differ-
ences in the global incidence of the disease [5, 6].
Overall, more than half of patients with an initial diagnosis of
colorectal cancer develop liver metastases [7]. Liver metastases
at diagnosis (i.e., synchronous metastases) are present in about
25 % of patients with colorectal cancer [8], and another 30 %
will develop them subsequently (i.e., metachronous metastases).
Patients with synchronous metastases usually present poorer
biological features than patients with metachronous metastases.
Surgical resection improves overall survival in patients with
colorectal liver metastases (CRLM) [9]. Best patient outcomes
are more frequently achieved when decisions involve a multi-
disciplinary team. Resectability criteria for patients with CRLM
have been expanded in past years [10, 11]. Previously, eligibil-
ity for hepatic resection was determined by the number of liver
metastasis detected, the size of the tumor lesion, and the margin
of resection [12]. According to recent updates, resectability
criteria have been expanded to include any patient in whom
all lesions can be removed with a negative margin and those
who present with an appropriate liver volume or liver functional
reserve [12]. Consequently, more patients are now eligible for
resection by increasing or preserving liver reserve through por-
tal vein embolization or through two-stage hepatectomy. Also,
patients may become eligible with a combination of resection
with ablation and decreasing tumor size by the administration
of neoadjuvant and/or conversion chemotherapy. Moreover, in
recent years, resectablity criteria also include patients with ex-
trahepatic disease, as long as resection is feasible.
Although the number of patients with synchronous CRLM
eligible for resection is increasing, the optimal treatment se-
quence in these patients is not clearly defined. Thus, surgical
strategies for these patients may be described as (i) combined,
i.e., resection of both primary and liver tumors; (ii) classic, i.e.,
resection of primary tumor before liver metastasis resection;
and (iii) reverse, i.e., liver resection prior to primary tumor
resection [13]. All three strategies have demonstrated efficacy
in this population of patients. With regard to the long-term
outcome of patients who undergo hepatic resection for
CRLM, this procedure is considered to be safe and to provide
good long-term survival rates, even in patients with multiple
bilobar metastases [14]. Survival rates in patients undergoing
a partial hepatectomy are similar to survival rates observed in
patients with primary hepatic resection of CRLM [15].
In patients with unresectable CRLM, standard chemother-
apy regimens which combine 5-fluorouracil with oxaliplatin
or irinotecan (i.e., FOLFOX or FOLFIRI, respectively) facil-
itate secondary resection of liver metastases [16]. The addition
of a targeted agent, for example bevacizumab, a recombinant
humanized monoclonal antibody that targets the vascular en-
dothelial growth factor receptor (VEGFR), or monoclonal an-
tibodies that target the epidermal growth factor receptor
(EGFR), may further increase the proportion of patients eligi-
ble for resection of liver metastases [17–19]. For patients with
initially suboptimal or unresectable CRLM, a targeted agent
plus chemotherapy also yields high response rates and leads to
increased resectability [20]. In patients with initially resectable
CRLM, chemotherapy improves progression-free survival
(PFS) but not overall survival (OS) [21], and the further addi-
tion of an EGFR-directed antibody is not beneficial [22].
The aim of this paper is to review the role of antiangiogenic
agents in the neoadjuvant treatment of patients with CRLM as
well as in the conversion from initially unresectable tumors to
resectable ones. In addition, the impact of these agents on
pathological response, liver protection, as well as morbidity
and mortality is reviewed.
Methods
A search of PubMed, ISI WoK, and Clinicaltrials.gov was per-
formed in October 2012 for publications relating to the use of
antiangiogenic agents in the neoadjuvant or conversion treatment
of patients with CRLMbetween January 2002 and January 2012.
Articles were included if published in English or Spanish. The
search was divided up into six areas: (i) incidence of liver metas-
tasis on colorectal cancer, (ii) role of surgery on liver metastasis,
(iii) role of antiangiogenic drugs on liver metastasis treatment
before surgery, (iv) efficacy of antiangiogenic drugs on liver me-
tastasis of colorectal cancer, (v) clinical response and pathology
response, and (vi) liver toxicity of chemotherapy (bevacizumab
proctection of the liver, safety of antioangiogenics). Search terms
included were as follows: antineoplastic combined chemotherapy
protocols/administration and dosage; neoadjuvant therapy; neo-
plasm metastasis; colorectal neoplasms/drug therapy; colorectal
neoplasms/pathology; colorectal neoplasms/surgery; colorectal
neoplasms/therapy; liver neoplasms/drug therapy; liver
neoplasms/secondary; angiogenesis inhibitors; antibodies, mono-
clonal; antibodies, monoclonal, humanized; and bevacizumab.
Articles were reviewed by the authors for their relevance and
for quality of evidence. The authors met to discuss their findings
and conclusions from their review.
Mechanism of action of antiangiogenic agents in colorectal
cancer
Angiogenesis is an essential process in solid tumors larger
than 1–2 mm. Beyond this size, diffusion of oxygen alone is
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not enough to maintain adequate oxygen levels within the
tumor tissue [23, 24]. Angiogenesis is a process stimulated
by hypoxia and regulated by the balance between
proangiogenic and antiangiogenic molecules. These mole-
cules are present in endothelial cells, pericytes, and immune
cells. The establishment and survival of metastases imply that
a shift in the balance of these factors in favor of angiogenesis
has occurred. Angiogenesis comprises several steps, including
the detachment of endothelial cells and pericytes from the
basement membrane, their invasion, and migration across
basement membranes into the tumor mass and their differen-
tiation to generate a new capillary network. Tumor neovascu-
larization is a critical process in cancer progression. In fact, an
increase in angiogenesis in the primary tumor has been related
to poor prognosis and recurrence in colorectal cancer patients
[25–28].
Vascular endothelial growth factor (VEGF) is the primary
proangiogenic molecule affecting several steps throughout the
angiogenic process (Table 1). The VEGF family is composed
of six molecules (VEGF-A, VEGF-B, VEGF-C, VEGF-D,
VEGF-E, and placental growth factor [PlGF]) and three re-
ceptors (VEGF-R1, VEGF-R2, and VEGF-R3) [29–31]. One
of the VEGF-A isoforms, VEGF165, is commonly expressed
in solid tumors [32].
Research has demonstrated that both neuropilin-1 and
neuropilin-2 act as accessory receptors for the VEGF165 iso-
form [33], and also that overexpression of neuropilin-1 in
colorectal cancer cells increases tumor growth and angiogen-
esis [34]. Another characteristic of neuropilin-1 is that this
molecule is upregulated by the activation of EGFR, another
therapeutic target for colorectal cancer.
Bevacizumab exerts its action against VEGF-A, which re-
sults in the prevention of VEGFR activation and the subse-
quent signaling cascades [35]. Aflibercept prevents VEGFR
activation by binding to VEGF-A and PlGF [36].
Main antiangiogenic agents in colorectal cancer
Three main antiangiogenic agents have been shown to im-
prove the outcomes of patients with mCRC when given in
combination with chemotherapy, namely, bevacizumab,
aflibercept, and regorafenib.
Some of the main studies involved in the clinical develop-
ment of bevacizumab are described briefly below. Hurwitz
et al. conducted a phase III trial in 813 patients with previously
untreated mCRC [37]. Patients were randomized to receive
irinotecan plus bolus 5-fluorouracil and leucovorin (IFL) with
or without bevacizumab. The addition of bevacizumab result-
ed in a statistical and clinical improvement in terms of median
OS (20.3 vs 15.6months, respectively; p<0.001), median PFS
(10.6 vs 6.2 months, respectively; p<0.001), overall response
rate (RR) (45 vs 35%, respectively; p=0.004), and the median
duration of the response achieved (10.4 vs 7.1 months; p=
0.001). A significant improvement in terms of PFS (9.4 vs
8.0 months, respectively; p=0.0023) was also observed when
bevacizumab was added to oxaliplatin-based schedules in a
placebo-controlled phase III trial that included 1401 untreated
patients with mCRC [38]. Moreover, results in terms of PFS
were also superior in the group of patients who were treated
with the addition of bevacizumab to their chemotherapy reg-
imen until study termination [38]. Based on the data obtained
in these phase III trials, together with data from other impor-
tant randomized phase II trials and observational studies,
bevacizumab in combination with fluoropyrimidine-based
chemotherapy has been approved by the US Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) for the treatment of patients with mCRC.
Aflibercept is a fusion protein composed of segments of
human VEGF-R1 and VEGF-R2 fused to the constant region
of human immunoglobulin G1. So far, only the phase III trial
VELOUR, a study carried out to evaluate the second-line
treatment of patients with mCRC with this agent, has reported
efficacy results [39]. This trial compared the addition of
aflibercept or placebo to FOLFIRI in 1226 patients with
mCRC as second-line treatment. In this setting, the addition
of aflibercept improved median OS (13.5 vs 12.1 months; p=
0.0032), median PFS (6.9 vs 4.7 months; p<0.001), and RR
(20 vs 11%; p=0.0001) in patients withmCRC after receiving
first-line treatment with oxaliplatin.
Lastly, regorafenib is a multikinase inhibitor of a wide
range of angiogenic, oncogenic, and stromal kinases. The
placebo-controlled randomized phase III trial CORRECTwith
regorafenib was conducted in 760 patients with mCRC who
had progressed after receiving all available standard therapies.
Median OS, the primary study endpoint, was 6.4 months in
the regorafenib group versus 5.0 months in the placebo group
(p=0·0052) [40].
To date, aflibercept in combination with FOLFIRI has been
approved by the FDA and the EMA for the treatment of
Table 1 Main functions of VEGF in endothelial cells [adapted from 88]
Function Activity
Activation Upregulation of integrin expression
Alteration in cell cytoskeleton
Invasion Induction of metalloproteinases
Migration Activation of FAK and p38
Permeability Endothelial fenestrations
Separation of junctions between cells
Vesico-vascular organelles
Proliferation Activation of MAPK
Survival Induction of PI3K/PKB and survivin
Inhibition of caspases
FAK focal adhesion kinase, MAPK mitogen-activated protein kinase,
PI3K phosphoinositide 3-kinase, PKB protein kinase B, VEGF vascular
endothelial growth factor
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patients with mCRC who are resistant to or have progressed
after an oxaliplatin-containing regimen. Regorafenib has also
been approved by the FDA and the EMA in patients with
mCRC after failure to respond to standard therapies.
Main antiangiogenic agents in the neoadjuvant
and conversion treatment of CRLM
Resection of CRLM along with the administration of antineo-
plastic agents has become the standard of care for patients
with CRLM. In this setting, bevacizumab is currently the only
antiangiogenic agent that has been demonstrated, through ret-
rospective and prospective phase II trials, to improve the out-
come of patients with mCRC. Table 2 summarizes the main
efficacy data from some of these trials.
Retrospective studies
Several retrospective analyses have provided evidence for the
efficacy of bevacizumab when added to neoadjuvant and con-
version chemotherapy for the treatment of patients with
CRLM. The randomized phase III trial NO16966 compared
the safety and efficacy of oxaliplatin-based chemotherapy
with or without bevacizumab in 1400 patients with mCRC.
A subsequent retrospective analysis of the resection rate in this
study was performed [17]. In the intention-to-treat (ITT) pop-
ulation, 44 out of 699 (6.3 %) patients treated with chemother-
apy plus bevacizumab underwent R0 metastasectomy, com-
pared with 34 out of 701 (4.9 %; p=0.24) patients treated with
chemotherapy plus placebo. In the subgroup of patients with
liver-only disease, curative resection rates were 12.3 and
11.6 % (p=0.81), respectively.
Terrebonne et al. conducted a cohort study to assess the
effectiveness of bevacizumab in combination with chemother-
apy to achieve a secondary metastatic resection with curative
intention in initially unresectable patients with mCRC [41]. Of
411 patients included, 347 were analyzable after 24 months of
follow-up. Of these, 19 % were able to undergo a metastatic
resection of which 86 % were R0-R1. Surgical patients previ-
ously received bevacizumab with either irinotecan-based reg-
imens (97 %) or oxaliplatin-based regimens (3 %). Addition-
ally, patients who underwent curative surgery achieved an RR
of 85 %, which decreased to 49 % in nonsurgical patients.
Median PFS in surgical patients was 13.6 and 9.0 months in
nonsurgical patients. Also, there were important differences in
the 1- and 2-year survival rates between both populations.
Additionally, for patients with initially unresectable CRLM,
secondary resection was possible in 19 %, of whom 86 %
achieved a R0-R1 resection. The authors concluded that the
addition of bevacizumab to chemotherapy made secondary
resection possible in 19 % of patients with initially
unresectable mCRC.
Chaudhury et al. retrospectively reviewed 35 patients with
CRLM who underwent liver resection and received
bevacizumab plus chemotherapy in the perioperative period
[42]. Chemotherapy consisted of an oxaliplatin-based regimen
(74 % of patients), an irinotecan-based regimen (17 %), or an
oxaliplatin-plus irinotecan-based regimen (9 % of patients).
The RR observed was 66 %. Forty-nine percent of patients
underwent a portal vein embolization prior to surgery, and
34 % were able to undergo staged resection for extensive
bilobar disease. The 4-year survival rate was 53 %. These
findings indicate that bevacizumab together with standard
neoadjuvant chemotherapy may improve RR in these patients
and may have a favorable impact on patients’ survival.
Lastly, Garcia et al. conducted another retrospective analy-
sis in 20 patients who received chemotherapy plus
bevacizumab as neoadjuvant and conversion treatment. In this
trial, curative resections could be performed in 95 % of pa-
tients [43]. Of the resections performed, 90 % were R0 (10 %
were R1). Interestingly, all synchronous primary tumors could
be resected. The median disease-free survival (DFS) and OS
in this series were 12.2 and 48.9 months, respectively.
Prospective studies
There are four phase II trials that have prospectively evaluated
the role of bevacizumab in the perioperative treatment of pa-
tients with CRLM. The BOXER study evaluated the admin-
istration of bevacizumab with capecitabine plus oxaliplatin
(XELOX) in 46 patients with CRLM who were considered
unsuitable for resection due to a poor-risk prognosis [44].
Criteria for poor risk included more than four metastases,
anymetastases larger than 5-cm diameter, R0 resection unlike-
ly, synchronous colorectal metastases, high probability of in-
adequate liver function in case of resection, as well as inability
to retain liver vascular supply. After perioperative treatment,
an RR of 78 % was achieved, and 12 out of 30 patients con-
sidered unresectable before treatment were regraded to poten-
tially resectable, which represented a conversion rate of 40 %.
Of these patients, 20 % achieved an R0 resection. In addition,
10 of 15 (67 %) patients with synchronous resectable CRLM
underwent liver resection, and four patients underwent a
“watchful waiting” approach due to an outstanding response
to neoadjuvant and conversion treatment. Overall, in all eligi-
ble patients, the median PFS was 12.0 months, and the 1-year
survival rate was 86 %.
Another nonrandomized phase II trial carried out by
Gruenberger et al. included 43 patients with CRLM potential-
ly curable by resection [45]. Patients were treated with
bevacizumab plus XELOX for 5 cycles. The sixth cycle in-
cluded only XELOX, leaving at least 5 weeks before surgery
without bevacizumab. After treatment, 66 % of patients
achieved a response and 97 % of patients underwent poten-
tially curative liver resection (R0, n=34; R1, n=1). Patients
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who received postoperative treatment achieved a significantly
longer OS compared with patients receiving neoadjuvant
treatment alone (47.9 vs 27.7 months; p<0.05).
Another prospective phase II trial assessed the safety and
efficacy of the combination of bevacizumab with oxaliplatin,
irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in 57
patients with unresectable mCRC [46]. This combination was
administered for a maximum period of 6 months followed by
maintenance therapy with bevacizumab. An RR of 77 % was
achieved. After 10 months, the PFS rate was 74 %; median
PFS and OS were 13.1 and 30.9 months, respectively.
Lastly, 80 patients with initially unresectable CRLM were
randomized in the phase II OLIVIA trial to receive
bevacizumab with modified 5-fluorouracil, leucovorin, and
oxaliplatin (mFOLFOX6) or bevacizumab with FOLFOXIRI
[47]. The results suggested that the combination of
bevacizumab and FOLFOXIRI improved resection rates, RR
and PFS compared with patients treated with bevacizumab
plus mFOLFOX6. Therefore, bevacizumabwith FOLFOXIRI
should be further assessed in this setting.
Studies evaluating pathological response
According to recent data, a good pathological response pre-
dicts a better outcome in terms of OS in patients with ad-
vanced colorectal cancer who have undergone neoadjuvant
and conversion chemotherapy prior to resection of CRLM
[48–50]. Based on these results, Vera et al. conducted a retro-
spective assessment of 95 patients who received either
irinotecan- or oxaliplatin-based chemotherapy alone or to-
gether with bevacizumab [51]. A good pathological response,
i.e., complete pathological response or <25 % of residual vi-
able tumor cells, was detected in 49 % of patients receiving
bevacizumab in comparison with 27 % of patients receiving
chemotherapy alone (p=0.0302). The authors concluded that
the addition of bevacizumab to chemotherapy in the neoadju-
vant and conversion setting significantly improves pathologi-
cal response in this population of patients.
The histological or pathological response to chemotherapy
achieved in patients with CRLM may be graded according to
tumor regression. Based on this relationship, resected liver
metastases from patients included in two prospective
nonrandomized trials were analyzed retrospectively [50]. In
these trials, patients received either FOLFOX or XELOX,
with or without bevacizumab. Pathological response was an-
alyzed according to different tumor regression grades (TRGs),
and these were correlated with the durations of PFS and OS
observed in these patients. The authors noted that 38 % of
patients in the bevacizumab arm had a major histological re-
sponse, in comparison with 10 % of patients in the
chemotherapy-only arm (p<0.001). Moreover, there was a
significant prolongation of both PFS and OS in patients with
a major histological response compared with patients with a
partial or no histological response. Thus, classifying histolog-
ical response by TRGs may help to predict the outcome of
patients with CRLM. In this regard, Chang et al. proposed a
modified TRG (mTRG) that included two types of histologi-
cal classification of tumor necrosis, namely, usual necrosis
(UN), which represents a lack of treatment effect, and
infarct-like necrosis (ILN), which represents a therapeutic re-
sponse to chemotherapy [52]. Moreover, in a series of 109
cases, they observed that all cases of ILNwere associated with
perioperative treatment with chemotherapy and bevacizumab.
Also, they observed that patients with ILN achieved a superior
DFS compared with patients with UN (p=0.047).
In another study conducted by Ribero et al. [53], results
from 105 patients with CRLM treated preoperatively with 5-
fluorouracil plus oxaliplatin with or without bevacizumab
were analyzed. It was observed that the addition of
bevacizumab to chemotherapy significantly reduced the per-
centage of residual viable tumor cells in resected tumors com-
pared with chemotherapy alone (33 vs 45 %, respectively; p=
0.02). Also, after stratification according to the magnitude of
tumor viability, more patients treated with bevacizumab pre-
sented with <25 % of residual viable tumor cells compared
with the control arm (45 vs 23 %, respectively; p=0.020),
although the complete pathological RR was similar in both
arms (11 vs 12 %, respectively; p=0.590).
Finally, another study evaluated the association between
the duration of neoadjuvant and conversion chemotherapy
with FOLFOX with or without bevacizumab, the rate of path-
ological response and the incidence of hepatotoxicity [54]. In
this study, 219 patients with CRLM underwent liver resection
after a short (1–8 cycles) or long (≥9 cycles) duration of che-
motherapy with or without bevacizumab. It was observed that
a long duration of treatment increased the risk of hepatotoxic-
ity (42 vs 26 %, respectively; p=0.017), but it did not affect
the pathological RR (55 vs 57%, respectively; p=0.74). It was
also noted that the addition of bevacizumab was associated
with a statistically significant increase in the rate of complete
or major pathological responses, independent of the duration
of treatment administered. Thus, the addition of a targeted
therapy, such as bevacizumab, had a greater influence on path-
ological RR than the duration of therapy.
Evaluation of response in patients with CRLM treated
with antiangiogenic agents
Since Response Evaluation Criteria in Solid Tumors
(RECIST) were published in 2000, they have been widely
accepted by clinicians, the pharmaceutical industry, and gov-
ernment authorities [55]. However, in recent years, it has been
debated whether or not it would be more appropriate to move
from one-dimensional assessment criteria to either volumetric
or functional assessments using techniques such as positron
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emission tomography (PET) or magnetic resonance imaging
(MRI). Most clinicians foresee that new cancer treatments,
such as targeted therapies, will require the development and
validation of new techniques to assess tumor response accu-
rately. In line with this, several response evaluation criteria
have been assessed in recent years through research in differ-
ent tumor types.
In cancer patients treated with antiangiogenic agents
RECIST do not take into consideration factors such as the
decrease in tumor density or the amount of intratumoral ves-
sels which are associated with treatment with antiangiogenic
agents. Nonetheless, PET has been demonstrated to have a
high sensitivity for detecting early responses, as well as for
predicting long-term outcomes in patients with mCRC [56].
However, the use of PET is limited by its cost. Another feasi-
ble option is computed tomography (CT), which combines an
evaluation of tumor density with tumor size criteria. This tech-
nique may allow the detection of early responses, and may
also have excellent prognostic value.
Smith et al. conducted a retrospective study in patients with
metastatic renal cell carcinoma treated with antiangiogenic
agents [57]. The standard contrast-enhanced CT (CECT) im-
ages from these patients were analyzed using four types of
assessment criteria. The analysis demonstrated that the assess-
ment was more accurate using Mass, Attenuation, Size and
Structure (MASS) criteria. In another study, Wahl et al.
reviewed the evaluation of tumor response according toWorld
Health Organization, RECIST, and RECIST 1.1 criteria in
patients with solid tumors [58]. The metabolic tumor response
was also analyzed with F-18-fluorodeoxyglucose PET ([18]F-
FDG PET), and the authors suggested PET Response Criteria
in Solid Tumors (PERCIST). The results showed that evalua-
tion by anatomic imaging criteria alone has limitations, espe-
cially for new cancer therapies focused on the stabilization of
disease. In contrast, (18)F-FDG PET had high value in this
setting. However, further research is warranted. Lastly, anoth-
er study assessed whether the tumor response achieved by
patients with unresectable lung adenocarcinoma treated with
chemotherapy plus an antiangiogenic agent could be evaluat-
ed by wide-volume perfusion CT [59]. The authors concluded
that perfusion CT imaging could detect alterations in the vas-
cularity of the tumor after treatment administration.
In patients with CRLM treated with antiangiogenic agents
Several trials have also been carried out in patients with
CRLM treated with antiangiogenic agents in order to deter-
mine the optimal evaluation criteria for these patients in the
neoadjuvant setting. One of these studies was conducted with
the aim of evaluating new tumor response criteria based on
morphological changes detected by CECT [60]. Patients
selected for the study presented with a diagnosis of CRLM
and were treated with bevacizumab in combination with che-
motherapy in the neoadjuvant setting. CT-based morphologi-
cal criteria were significantly associated with pathological re-
sponse and OS. Nonetheless, morphological changes in the
tumor are not always correlated with complete pathological
response. Another study aimed to determine whether perfu-
sion CT and magnetic resonance diffusion-weighted imaging
have value in the assessment of response after administering
chemotherapy plus an antiangiogenic agent as neoadjuvant
therapy in patients with CRLM [61]. Both techniques were
found to be useful for detecting therapy-induced modifica-
tions in the vascularization of metastases, which occur prior
to changes in lesion size.
An assessment of the role of dynamic contrast-enhanced
MRI in the evaluation of tumor response to treatment with
antiangiogenic drugs was carried out in patients with CRLM
[62]. This technique may be used to study the pathophysiolo-
gy of tumors by measuring the microvascular density of the
tumor and its vascular permeability. Results of this study
showed that responders presented with a reduction in tumor
perfusion within 26–33 h after the first dose of treatment. Such
results suggest that dynamic contrast-enhanced MRI may be a
more precise measure of pathological response to
antiangiogenic agents than the determination of tumor diam-
eter in the neoadjuvant treatment of patients with CRLM.
Lastly, the Multidisciplinary Spanish Group for Gastroin-
testinal Malignancies (GEMCAD) is currently performing the
AVAMET study (identifier NCT01493713), which will eval-
uate the correlation between RR according to RECIST v1.1.
evaluated by conventional imaging techniques, and morpho-
logical response by CT or histopathological response in pa-
tients with CRLM treated with XELOX plus bevacizumab.
However, at the time of writing, no results are available.
Prognostic criteria and response markers in patients
with CRLM
Prognostic criteria in patients with mCRC eligible for hepatic
resection have been developed in order to ensure optimal ben-
efit in terms of OS and PFS. These criteria have been useful
because they allow patient stratification into risk categories
and ensure an appropriate approach for every patient. Never-
theless, selecting the appropriate candidates for hepatic resec-
tion of CRLM has not been an easy task. Since 1980, several
prognostic scoring systems have been developed [63–68].
There are obviously significant differences between them,
and the general applicability of some of the scoring systems
has not been clearly validated, either internally or externally,
prior to their general use.
On the other hand, several promising new prognostic fac-
tors have been identified. These include the following: (i)
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markers of systemic inflammatory response, which are asso-
ciated with poor outcomes [69]; (ii) microarray analysis to
identify biological, histological, genetic, or proteomic “signa-
tures”; and (iii) high-throughput screening techniques
[70–73]. These new tools allow better predictive accuracy
compared with current prognostic factors. Hence, in the fu-
ture, prognostic scoring systems, biological and clinical fac-
tors should be tested in larger samples of patients. Neverthe-
less, external confirmation is also required prior to the wide-
spread use of any new prognostic scoring system.
With regard to responsemarkers, it is interesting tomention
a study conducted in 525 patients to determine whether TRGs
in patients with CRLM can predict clinical outcome in terms
of DFS and OS [74]. Histological tumor regression of hepatic
metastases was associated with fibrosis overgrowth, but not
with an increase of necrosis. Hence, fibrosis overgrowth
should be taken into account when evaluating the efficacy of
chemotherapy regimens against CRLM, and histological tu-
mor regression is associated with a better clinical outcome.
Nonetheless, in line with the presence of necrosis in the
tumor, a retrospective clinical and histological review was
conducted by Chang et al. in 121 partial hepatectomies per-
formed for CRLM [52], of which 109 had appropriate data
available. Among all 109 cases, 12 (11 %) presented with ILN
and 95 (87 %) showed UN. All 12 cases of ILN were associ-
ated with perioperative chemotherapy, and six of them were
related to the administration of bevacizumab (p=0.002). How-
ever, no association was found between ILN and other che-
motherapeutic agents. Interestingly, ILN was related to im-
proved DFS and OS in comparison with UN. Such results
strongly suggest that ILN is a form of tumor response to che-
motherapy and that this type of necrosis may be a prognostic
factor in this population of patients. These findings also sug-
gest that ILN was associated with bevacizumab treatment. In
other words, hypoxia from antiangiogenic treatment contrib-
utes significantly to the development of ILN.
Finally, Blazer et al. conducted a retrospective study with
305 patients who received preoperative oxaliplatin- or
irinotecan-based chemotherapy to assess whether pathological
response to chemotherapy was associated with survival in
patients with resected CRLM [48]. Patients were treated with
neoadjuvant chemotherapy followed by surgical resection,
and results demonstrated that pathological response (major
response p=0.034; hazard ratio, 4.80; minor response p=
0.007; hazard ratio, 6.93) was an independent predictor of
survival in this population of patients.
The protective effect of antiangiogenic agents on hepatic
injury
The use of cytotoxic agents before resection of CRLM has
been linked with liver injury, in particular preoperative
irinotecan and oxaliplatin with chemotherapy-associated
steatohepatitis and vascular parenchymal injury [75].
Fernandez et al. evaluated the effect of administering preop-
erative irinotecan and oxaliplatin on the development of
steatohepatitis in 37 patients with CRLM [76]. Biopsy scores
for nonalcoholic steatohepatitis were significantly worse in
patients treated with irinotecan- or oxaliplatin-based chemo-
therapy compared with no chemotherapy or 5-fluorouracil
alone (p=0.003). Moreover, steatohepatitis affected the ability
to perform large liver resections. In another study, Vauthey
et al. evaluated whether preoperative chemotherapy could
cause hepatic injury, affecting the postoperative outcome of
406 patients with CRLM [77]. At the end of the study, it was
determined that the administration of oxaliplatin was associ-
ated with sinusoidal dilation, whereas treatment with
irinotecan was associated with steatohepatitis. In addition, it
was found that steatohepatitis was associatedwith a higher 90-
day mortality rate after hepatic surgery. Hence, the chemother-
apy regimen to be administered to this patient population
should be carefully considered because the risk of hepatotox-
icity can be significant.
Data regarding pathology, as well as surgical outcomes,
were obtained in a study by Aloia et al. [78]. Ninety-two
patients treated with 5-fluorouracil- or oxaliplatin-based regi-
mens were randomly selected from a cohort of 303 patients
who underwent CRLM resection. No differences were found
in terms of steatosis regardless of whether patients had re-
ceived preoperative chemotherapy or not (13 vs 12 %, respec-
tively; p=0.86). In contrast, hepatic vascular lesions were
more frequent in patients who had received chemotherapy in
comparison with chemotherapy-naïve patients (52 vs 18 %,
respectively; p=0.01). Patients who had been treated preoper-
atively presented with a higher incidence of sinusoidal vaso-
dilation and congestion compared with chemotherapy-naive
patients (23 vs 12 %). The authors concluded that the main
hepatic lesions induced by 5-fluorouracil- and oxaliplatin-
based chemotherapy regimens are vascular lesions and not
steatosis, and that the risk of postoperative complications is
related to the duration of preoperative chemotherapy
administration.
With the aim of assessing the effects of preoperative sys-
temic chemotherapy on the liver, Karoui et al. [79] conducted
a study in 67 patients who underwent hepatic resection for
colorectal cancer. Pathological examination of the liver paren-
chyma demonstrated that sinusoidal dilation was present in
49% of patients who had received preoperative chemotherapy
in comparison with 25 % of the patients who did not receive
chemotherapy in the 6 months before resection (p=0.005).
However, steatosis rates were similar in both groups. Ideally,
the duration of treatment should be long enough to maximize
response, but short enough to minimize toxicity and surgical
morbidity. In line with this, Karoui et al. also observed that in
the chemotherapy group, morbidity was increased among
460 Targ Oncol (2015) 10:453–465
patients who were administered ≥6 cycles of chemotherapy in
comparison with patients who received <6 cycles (54 vs 19%;
p=0.047). Patients who did not present with adverse events
(AEs) during their postoperative course had received a median
of five cycles (range, 3–29) of preoperative chemotherapy. In
contrast, patients with postoperative morbidity had received a
median of 12 cycles (range, 6–22) of chemotherapy during
this period. Hence, this study shows that prolonged systemic
chemotherapy leads to pathological changes in the parts of the
liver with no metastases, such as sinusoidal dilation and atro-
phy of hepatocytes, as well as increasing postoperative com-
plications. In addition, the risk of postoperative morbidity is
related to the number of cycles of chemotherapy administered
preoperatively. Nonetheless, whether or not judiciously ad-
ministered chemotherapy affects long-term outcomes is still
the subject of debate and clinical investigation.
Recent data suggest that bevacizumab may protect against
sinusoidal damage. With the aim of studying sinusoidal dam-
age in patients with CRLM, Ribero et al. compared the out-
comes of 62 patients treated with FOLFOX plus bevacizumab
with 43 patients treated with FOLFOX alone [53]. Patients
treated with bevacizumab showed a significantly lower rate
of sinusoidal injury, both of any grade (27 vs 54 %; p<0.01)
and of grades 2–3 (8 vs 28 %; p<0.01). In line with this,
Klinger et al. also found a statistically significantly lower rate
of severe sinusoidal dilation in patients treated with FOLFOX
plus bevacizumab in comparison with patients treated with
FOLFOX alone (2 vs 24 %, respectively) [80]. The authors
concluded that bevacizumab may protect against sinusoidal
obstruction syndrome, providing a histological rationale for
the safe use of bevacizumab prior to liver resection.
In addition, several studies have suggested the possibility
of hepatic regeneration after bevacizumab administration. One
of these studies, conducted by Aussilhou et al., found a lower
incidence of hepatic hypertrophy following portal vein embo-
lization in 13 patients treated with FOLFOX or FOLFIRI plus
bevacizumab, in comparison with 27 patients treated with
these chemotherapy regimens without bevacizumab [81]. In
addition, patients treated with a longer duration of chemother-
apy plus bevacizumab presented with substantially less hepat-
ic hypertrophy after undergoing portal vein embolization than
patients treated with shorter schedules.
Safety profile of antiangiogenic agents
Angiogenesis is a complex process where VEGF plays an
important role in multiple biological pathways, such as hema-
topoiesis, myelopoiesis, and endothelial cell survival. Because
of this, antiangiogenic therapy shows a different toxicity pro-
file than standard chemotherapy regimens. However,
bevacizumab, the most established antiangiogenic agent, does
not substantially alter the toxicity profile of chemotherapy in
patients with mCRC [82]. Additionally, bevacizumab-
associated hematological or gastrointestinal toxicities do not
overlap with the toxicities of chemotherapy agents. In the
BEAT study [83], in which bevacizumab was combined with
FOLFOX, XELOX, FOLFIRI, or fluoropyrimidines alone,
the main severe AEs associated with bevacizumab occurred
in 11 % of patients and included bleeding (3 %), gastrointes-
tinal perforation (2 %), arterial thromboembolism (1 %), hy-
pertension (5 %), proteinuria (1 %), and wound-healing com-
plications (1 %), and the rates were similar regardless of the
chemotherapy schedule administered. Bleeding events were
generally mild in resected and unresected patients, and gastro-
intestinal perforation was observed in 4 % of patients with
unresected primary tumors. Moreover, perforation occurred
at the tumor site in three patients. The 60-day mortality was
3 % in the ITT study population.
To evaluate perioperative complications associated with
bevacizumab, a retrospective study was carried out in 35 pa-
tients with mCRC who received chemotherapy plus
bevacizumab. At the institution where the study was per-
formed, a break of 6–8 weeks between the last dose of
bevacizumab and liver resection was suggested [42]. Of the
35 patients included in the study, 15 patients developed a total
of 23 complications after surgery, but only 5 of them (22 %)
were grade III or higher according to the Clavien system [84].
Ten patients experienced 13 infectious events, 2 patients
showed bile leaks, 1 patient presented with a perioperative
myocardial infarction, and another experienced anastomotic
dehiscence which required further surgery. Bowel obstruction
was detected in one patient, and two patients developed severe
liver dysfunction. One of these patients developed grade III
hepatic encephalopathy after a second resection. Overall, the
incidence of postoperative morbidity was high (42 %), but
there was no perioperative mortality.
Since it has been suggested that bevacizumab, due to its
antiangiogenic properties, can interfere with wound healing,
which is relevant in the perioperative setting [85, 86], some
preventive measures can be recommended in order to avoid
surgical morbidity. One recommendation is that bevacizumab
treatment should be stopped at least 5–8 weeks before surgery
and should not be restarted until 28 days after surgery or when
all incisions have healed completely [85–87]. However, shorter
timelines than these may be possible. Gruenberger et al. [45]
observed that in patients who had received neoadjuvant che-
motherapy plus bevacizumab, and bevacizumab was
discontinued about 5 weeks before surgery, surgical complica-
tion rates were similar to those observed in patients treated with
chemotherapy alone. The authors concluded that it is not yet
possible to determine if stopping bevacizumab for several
weeks before surgery is preferable to using the agent to enable
patients to undergo a complete resection. Overall, these studies
demonstrated that bevacizumab is feasible in the perioperative
setting, with marked effect on surgical complication rates.
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Aflibercept has demonstrated a similar toxicity profile to
other agents targeting the VEGF pathway. However,
aflibercept seems to increase chemotherapy-specific compli-
cations such as diarrhea, asthenic conditions, neutropenia, and
stomatitis/ulceration. In the previously mentioned VELOUR
trial [39], the most common AEs were anemia, diarrhea, neu-
tropenia, asthenia, and proteinuria. Hypertension was readily
managed with standard antihypertensives such as angiotensin-
converting enzyme inhibitors, calcium channel blockers, and
diuretics. Gastrointestinal perforations and fistulae occurred in
less than 2 % of patients. However, AEs leading to treatment
discontinuation occurred in 27 and 12 % of patients in
aflibercept and placebo groups, respectively. The most com-
mon causes for treatment discontinuation in patients treated
with aflibercept were asthenic conditions, infections, diarrhea,
and hypertension.
The most common severe AEs found with the administra-
tion of regorafenib in the phase III CORRECT trial [40] in-
cluded hand-foot skin syndrome (17 %), fatigue (10 %), diar-
rhea (7 %), hypertension (7 %), and rash or desquamation
(6 %). No unexpected AEs were detected in patients treated
with regorafenib. Nevertheless, data are scarce regarding the
use of aflibercept and regorafenib with hepatic resection.
In Table 3, reported grade 3/4 AEs in phase III trials of
bevacizumab, aflibercept, and regorafenib in the treatment of
patients with mCRC is summarized. However, it is important
to highlight that data are not really comparable as they are
obtained from different clinical trials and different patient
populations.
Conclusions
Perioperative treatment of patients with CRLM results in lon-
ger PFS and OS. In addition, in patients with high-risk fea-
tures, neoadjuvant and conversion treatment provides an op-
portunity to gather information on the biological activity of
the tumor and its response to treatment, as well as improving
resectability rates.
To date, three antiangiogenic agents have been demonstrat-
ed to improve the outcomes of patients with mCRC in pro-
spective randomized trials. Aflibercept in combination with
FOLFIRI as second-line treatment improves OS and PFS in
patients with mCRC after first-line treatment with an
oxaliplatin-based regimen, with or without an antiangiogenic
agent. Regorafenib has also demonstrated promising results in
patients with mCRC who had progressed after receiving all
approved standard treatments. However, bevacizumab is cur-
rently the only antiangiogenic drug which has demonstrated
benefits in the presurgical treatment of CRLM as well as in
patients with mCRC.
For patients with initially unresectable CRLM, chemother-
apy with or without a targeted agent may downsize metastases
and facilitate secondary resection. For these patients, the









Hematologic toxicity, n (%)
Leukopenia 145 (37)
Neutropenia – (37)
Proteinuria 3 (1) 4 (1) – (8) 7 (1)
Nonhematologic toxicity, n (%)
Arterial thrombosis 12 (2) – (2)
Bleeding 12 (3) 13 (2) – (3)
Diarrhea 126 (32) – (19) 36 (7)
Fatigue 48 (10)
Fistula/intra-abdominal abscess 6 (1) – (1)
Gastrointestinal perforation 6 (2) 4 (1) – (1)
Hand-foot skin reaction – (3) 83 (17)
Hyperbilirubinemia 40 (8)
Hypertension 43 (11) 26 (4) – (19) 36 (7)
Thrombophlebitis 35 (9)
Venous thrombosis 54 (8) – (8)
Wound healing complications 1 (1)
Any grade 3/4 toxicity, n (%) 334 (85) 555 (80) – (83) 270 (54)
AE adverse event, BSC best supportive care, mCRC metastatic colorectal cancer, IFL irinotecan plus bolus 5-fluorouracil and leucovorin, FOLFIRI
irinotecan plus infusional 5-fluorouracil and leucovorin, FOLFOX 5-fluorouracil, leucovorin, and oxaliplatin, XELOX capecitabine and oxaliplatin
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combination of FOLFOX or FOLFOXIRI plus bevacizumab
has led to high RRs and resection rates, as well as an accept-
able safety profile. FOLFOX plus bevacizumab is also effec-
tive for patients with unresectable CRLM and has a favorable
safety profile, whereas irinotecan carries a higher risk of he-
patic toxicity.
Encouraging results regarding the impact of bevacizumab
plus chemotherapy on pathological response have been re-
ported, with a clear benefit on OS. Additionally, several stud-
ies have shown that bevacizumab may have a protective effect
against liver injury, in particular steatohepatitis and vascular
parenchymal injuries, which are associated with the preoper-
ative administration of irinotecan and oxaliplatin. Regarding
the safety profile of bevacizumab, in order to avoid postoper-
ative morbidities, it has been recommended that bevacizumab
administration should not be restarted until 28 days after sur-
gery or when all incisions have healed.
Antiangiogenic agents represent an increasingly important
treatment option in the neoadjuvant and conversion therapy of
CRLM.
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